These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29655050)

  • 1. Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease.
    Vlassenko AG; Gordon BA; Goyal MS; Su Y; Blazey TM; Durbin TJ; Couture LE; Christensen JJ; Jafri H; Morris JC; Raichle ME; Benzinger TL
    Neurobiol Aging; 2018 Jul; 67():95-98. PubMed ID: 29655050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain.
    Goyal MS; Gordon BA; Couture LE; Flores S; Xiong C; Morris JC; Raichle ME; L-S Benzinger T; Vlassenko AG
    Neurobiol Aging; 2020 Dec; 96():165-175. PubMed ID: 33011615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.
    Whitwell JL; Graff-Radford J; Tosakulwong N; Weigand SD; Machulda MM; Senjem ML; Spychalla AJ; Vemuri P; Jones DT; Drubach DA; Knopman DS; Boeve BF; Ertekin-Taner N; Petersen RC; Lowe VJ; Jack CR; Josephs KA
    Alzheimers Dement; 2018 Aug; 14(8):1005-1014. PubMed ID: 29605222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
    Oh H; Madison C; Baker S; Rabinovici G; Jagust W
    Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain aerobic glycolysis and resilience in Alzheimer disease.
    Goyal MS; Blazey T; Metcalf NV; McAvoy MP; Strain JF; Rahmani M; Durbin TJ; Xiong C; Benzinger TL; Morris JC; Raichle ME; Vlassenko AG
    Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2212256120. PubMed ID: 36745794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease.
    Fan Z; Okello AA; Brooks DJ; Edison P
    Brain; 2015 Dec; 138(Pt 12):3685-98. PubMed ID: 26510952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging.
    Cavedo E; Frisoni GB
    Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):237-49. PubMed ID: 21532538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.
    Dronse J; Fliessbach K; Bischof GN; von Reutern B; Faber J; Hammes J; Kuhnert G; Neumaier B; Onur OA; Kukolja J; van Eimeren T; Jessen F; Fink GR; Klockgether T; Drzezga A
    J Alzheimers Dis; 2017; 55(2):465-471. PubMed ID: 27802224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline.
    Hanseeuw BJ; Betensky RA; Schultz AP; Papp KV; Mormino EC; Sepulcre J; Bark JS; Cosio DM; LaPoint M; Chhatwal JP; Rentz DM; Sperling RA; Johnson KA
    Ann Neurol; 2017 Apr; 81(4):583-596. PubMed ID: 28253546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease.
    Tetzloff KA; Graff-Radford J; Martin PR; Tosakulwong N; Machulda MM; Duffy JR; Clark HM; Senjem ML; Schwarz CG; Spychalla AJ; Drubach DA; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
    J Alzheimers Dis; 2018; 62(4):1713-1724. PubMed ID: 29614676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCA7 Genotypes Confer Alzheimer's Disease Risk by Modulating Amyloid-β Pathology.
    Zhao QF; Wan Y; Wang HF; Sun FR; Hao XK; Tan MS; Tan CC; Zhang DQ; Tan L; Yu JT;
    J Alzheimers Dis; 2016 Mar; 52(2):693-703. PubMed ID: 27003212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
    Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.
    Smith R; Wibom M; Olsson T; Hägerström D; Jögi J; Rabinovici GD; Hansson O
    J Alzheimers Dis; 2016; 51(2):339-43. PubMed ID: 26836192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain aerobic glycolysis and motor adaptation learning.
    Shannon BJ; Vaishnavi SN; Vlassenko AG; Shimony JS; Rutlin J; Raichle ME
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3782-91. PubMed ID: 27217563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.